纤溶酶系统与阿尔茨海默症

Progress in plasmin system and Alzheimer's disease research

阿尔茨海默症(Alzheimer's disease,AD)是一种中枢神经系统进行性的退变疾病,其病因目前尚未确定。越来越多的遗传学和生物化学证据显示β淀粉样蛋白(amyloid β,Aβ)是AD发病的主要病理因子。本文介绍了大脑纤溶酶系统与Aβ相互作用的分子机理,通过上调大脑中纤溶酶的表达,可以清除Aβ,这可能为防治AD提供了新的治疗靶点。最新研究结果表明PAI-1的小分子抑制剂和他汀类药物可以通过纤溶酶系统来调控Aβ的降解,这类药物有望成为治疗和预防AD的新药。

Alzheimer＇s disease （AD） is a progressive neurodegenerative disorder and the cause of disease is far from clear. Accumulating genetic and biochemical evidences support the notion that amyloid-β （Aβ） is the central feature in the pathogenesis of AD. This article introduces the molecular mechanism of the interaction between plasminogen system in brain and Aβ. The upregulation of plasmin in brain which can clean Aβ may provide a novel and viable therapeutic strategy of prevention and treatment of AD. The latest studies have shown that small molecule inhibitor of PAI-1 and statins drugs can control the degradation of Aβ through the plasminogen system. These drugs are expected to become a new drug for prevention and treatment of AD.